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Abstract. The nuclear phosphoprotein p53 is frequently 
inactivated in human cancer. Although it was previously 
classified as an oncoprotein, p53 has emerged as a tumor 
suppressor controlling cell cycle progression by regulating 
gene transcription. A major biochemical property of wild-
type p53 is its ability to bind DNA in a sequence-specific 
manner. The human c-H-ras gene contains within its first 
intron sequences that partially match the p53 consensus 
binding site. We determined that these sequences represent a 
bona fide p53 element, since in vitro translated wild-type p53 
recognized them with high affinity. Furthermore, wild-type 
p53 activated transcription from a reporter plasmid 
containing the c-H-ras element as an enhancer. These 
findings suggest that p53 regulates cellular growth by 
coordinate transcription of genes that suppress and promote 
cellular proliferation. 
Introduction 
The p53 gene encodes a sequence-specific transcription 
factor that induces cell cycle arrest or programmed cell death 
in response to DNA damage (1-6). In more than half of all 
human tumors p53 is inactivated by missense mutations (7-10). 
Such tumors become refractory to stimuli that would 
normally induce apoptosis or cell cycle arrest (11). 
The protein encoded by the p53 gene has been studied 
extensively. The N-terminus of p53 contains a transactivation 
domain (12,13), the C-terminus a tetramerization domain 
(14-17), and the central region a sequence-specific DNA 
binding domain (18-21). The latter domain is inactivated by 
point mutations in human tumors (7-10). 
Correspondence to: Professor D.A. Spandidos, Institute of 
Biological Research and Biotechnology, National Hellenic 
Research Foundation, 48 Vas. Constantinou Avenue. 116 35 
Athens, Greece 
Key words: transcriptional element, Η-ras, proto-oncogene, p53 
tumor suppressor 
The ability of p53 to regulate cell cycle progression and 
programmed cell death-depends on its ability to enhance 
expression of specific target genes (22). A number of such 
genes have been identified, including p21/waf]/cipl 
(hereafter referred to as p21), bax, gadd45 and mdm2 (23-26). 
The p21 gene encodes an inhibitor of cyclin-dependent 
kinases (27,28). Its expression leads to arrest of cell cycle 
progression f<5,23). The bax gene encodes an antagonist of 
Bcl-2; Bax promotes, while Bcl-2 inhibits apoptosis (24). 
The gadd45 gene is implicated in DNA repair (25). In 
contrast to p21, bax and gadd45, all of which suppress 
cellular proliferation, the mdm2 gene is a proto-oncogene 
(29). It encodes a protein that stimulates cell growth by 
inhibiting the function of two tumor suppressors: p53 and Rb 
(26,30,31). A common feature of the p21, bax, gadd45 and 
mdm.2 genes is the presence of p53 binding sites within their 
regulatory elements (23-26). 
The H-rai gene, like p53, is frequently mutated in human 
cancer (32). However, unlike p53, it is a proto-oncogene. It 
encodes a protein that converts GTP to GDP and acts as a 
molecular switch in the growth factor signal transduction 
pathway (33). In human cancer H-rai or other members of 
the ras gene family are mutated such that their protein 
products promote cell proliferation (34-37). 
The H-rai gene contains within its first intron a sequence 
that partially matches the consensus p53 binding site (38). 
We have established that this sequence can function as a p53 
DNA binding and transcriptional element raising the 
possibility that expression of H-rai is regulated by the p53 
tumor suppressor. 
Materials and methods 
Recombinant plasmids. Standard cloning procedures were 
used (39). Plasmid pGEMhp53wtB encodes human wild-type 
p53 (40). Plasmids pGEMhp53Hisl75B, pGEMhp53Gln248B, 
pGEMhp53Trp248B and
 PGEMhp53His273B encode the 
tumor-derived p53 mutants His 175, Gln248, Trp248 and 
His273, respectively, and were derived from pGEMhp53wtB 
(40) by site-directed mutagenesis. 
Plasmid pSV2hp53wtB was prepared by cloning into the 
Sall-Bglll sites of pSV2humjun (41) a blunted EcoRI-Hindlll 
p53 insert from pGEMhp53wtB (40). Plasmids expressing 
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Figure 1. Organization of the human Η-ras gene and position of the p53 element. The exons are represented by rectangles, the coding sequences as filled 
rectangles and the VTR by a crosshatched box. The nucleotide sequence ofjhe p53 element is indicated. The p53-specific pentanucleotide repeats are 
demarcated by dashes and their homology to the p53 consensus site is indicated by asterisks. R, Pu; W, A/T; Y, Py. Nucleotide positions follow Capon el al 
(34). 
tumor-derived p53 mutant proteins were similarly derived 
from the corresponding pGEM plasmids. A pSV2 plasmid 
without insert was prepared by ligating pSV2humjun (41) 
linearized with Sail and Bglll. 
Plasmid pBC12/PLseap contains the coding sequences of 
secreted alkaline phosphatase with no enhancer or promoter 
sequences (42). Plasmid pTKseap was derived from 
pBC12/PLseap and contains a minimal thymidine kinase 
promoter (43). Plasmids pEp21/TKseap and pEras3HS/ 
TKseap have one copy of oligonucleotides Ep21 and 
Eras3HS, respectively, cloned in the EcoRV site of pTKseap 
just upstream of the minimal thymidine kinase promoter. The 
sequences of oligonucleotides Ep21 and Eras3HS are: CCC-
GAACA-TGTCC-CAACA-TGTTG-GGG and GCG-
GGGCC-TGCAG-GCTGGCAC-TAGCC-TGCCC-GGGCA-
CGCCG-TGG. respectively. The repeats recognized by p53 
are underlined. 
DNA binding assays. Plasmids of the pGEM series were used 
to generate in vitro translated p53 proteins (21,40,44). These 
proteins were subsequently incubated with 3 2P-labeled 
oligonucleotides and subjected to electrophoresis as 
previously described (21,40,44). Oligonucleotide TF3 is a 
non-specific DNA (44). Antibody PAb421 was obtained 
from Oncogene Science (Uniondale, NY). 
Transcription assays. Saos-2 cells were transiently 
transfected by calcium phosphate precipitation (43). Each 
transfection was performed using 10 μg of the pSV2 series 
plasmids driving p53 expression and 20 μg of the reporter 
plasmids. Alkaline phosphatase activity was determined 48 h 
later as described (43). 
Results 
Identification of a putative p53 element in Η-ras. DNA sites 
recognized by the p53 tumor suppressor consist of two half-
sites, which may be contiguous or separated by as much as 
21 nucleotides (38,40,45). Each half-site is ten nucleotides 
long and contains two pentamer repeats arranged head-to-
head. The sequence of the optimal half-site is GGGCA-
TGTCC (38,44). Wild-type p53, however, can also bind to 
sites that differ from the optimal sequence. It has been 
suggested that p53 recognizes DNAs containing two half-
sites that fit the consensus PuPuPuC(A/T)-(A/T)GPyPyPy, 
where Pu and Py, are purines and pyrimidines, respectively 
(45). -τ 
A computer search of the genes in the GenBank database 
has revealed that human H-ras contains two consecutive 
pentanucleotides that fit the p53 consensus (38). We were 
intrigued by this observation and inspected the adjacent DNA 
sequences. We were able to identify four more penta­
nucleotides that together with the ones previously identified, 
form three putative p53 half-sites (Fig. 1). Two of these half-
sites are contiguous, while the third one is located 8 
nucleotides upstream. Although none of the half-sites fit the 
consensus PuPuPuC(A/T)-(A/T)GPyPyPy, their close 
juxtaposition raises the possibility that they may be 
recognized by human p53. 
Recognition of the putative H-ras element by p53. The ability 
of human p53 to bind the putative H-ras element was 
examined in an electrophoretic mobility shift assay. In vitro 
translated wild-type p53 bound a 32P-labeled oligonucleotide 
(Eras3HS) containing all three half-sites of H-ras (Fig. 2). 
Binding was enhanced by antibody PAb421, which 
recognizes the p53 C-terminus and is known to switch p53 
into a conformation with high affinity for DNA (21,40,44, 
46,47). Furthermore, PAb421 supershifted the p53/DNA 
complex, thereby confirming the identity of the DNA binding 
protein as p53. To determine if recognition of the 32P-labeled 
H-ras DNA by wild-type p53 was sequence-specific, the 
binding reaction was performed in the presence of 500-fold 
excess of non-radioactive competitor DNAs. Binding was 
competed by oligonucleotide Ep21, which contains the p53 
element of the p21 gene (23), but not by oligonucleotide 
TF3, which does not contain a p53 DNA site. Binding was 
also competed, as expected, by oligonucleotide Eras3HS. In a 
related experiment we examined binding of p53 to , 2 P -
labeled oligonucleotide Ep21. Wild-type p53 recognized this 
DNA and furthermore binding was enhanced by antibody 
PAb421. Excess of non-radioactive Eras3HS DNA competed 
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Figure 2. Wild-type p53 recognizes an element of the Η-ras gene. In vitro translated wild-type p53 was intubated with 32P-labeled oligonucleotides Eras3HS 
or Ep2l. Where indicated 500-fold excess unlabeled specific (Ep2l) or non-specific (TF3) competitor DNA and/or antibody PAb421 were added. The 
reactions were resolved on native Polyacrylamide gels. 
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Figure 3. Binding of p53 to the Η-ras element requires an intact sequence-specific DNA binding domain. In vitro translated wild-type p53 or tumor-derived 
p53 mutants were incubated with 32P-labeled oligonucleotide Eras3HS and then resolved on native Polyacrylamide gels. Where indicated the binding reactions 
were performed in the presence of 0.1 μg antibody PAb421. H, His; Q, Gin; W, Trp. 
for binding of p53 to labeled Ep21, while excess of a non­
specific DNA (oligonucleotide TF3) did not (Fig. 2). We 
conclude that p53 recognizes with specificity an element 
within the human Η-ras gene. Furthermore, the affinity of 
p53 for this element is comparable to the well-characterized 
p53 element of the p21 gene. 
Wild-type p53 contains a sequence-specific DNA binding 
domain within residues 90-290 and a sequence-independent 
DNA binding domain within its C-terminal 30 amino acids 
(18-21,48). To determine which domain recognizes the H-ras 
element, we examined tumor-derived p53 mutants, which 
carry single amino acid substitutions within the sequence-
specific DNA binding domain. Mutants Hisl75, Gln248, 
Trp248 and His273 are very frequently associated with 
human cancer (7-10). Their names indicate the residue 
encoded by the mutated codon and the codon number. All 
these mutants were impaired relative to wild-type p53 in their 
ability to bind the Eras3HS oligonucleotide (Fig. 3), 
suggesting that wild-type p53 recognizes the H-ras element 
through its sequence-specific DNA binding domain. 
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Tabic I. The H-ras p53 clement functions as a p53-dcpendent 
transcriptional enhancer. 
Enhancer/Promoter Expressed protein Activity 
Eras3HS/TK 
Ep21/TK 
None/TK 
None/None 
Wild-type p53 
p53His273 
ρ53Τφ248 
None 
Wild-type p53 
p53His273 
p53Trp248 
None 
Wild-type p53 
Wild-type p53 
175.7±3.0 
59.7±2.0 
62.3+13.0 
40.0+2.6 
1797.3±420.7 
91.3±7.2 
84.0+3.2 
49.7±7.7 
32.0+4.0 
0.0±0.0 
Wild-type p53 and the tumor-derived p53 mutants His273 and 
Trp248 were assayed for the ability to activate transcription from 
reporter plasmids containing Eras3HS or Ep21 enhancerelements. 
As controls we used a pSV2 expression plasmid without insert 
(expressing no protein) and reporter plasmids with no enhancer or 
no promoter. The results are presented as means±l SE in arbitrary 
units. TK, thymidine kinase. 
The H-ras p5Ì element functions as a transcriptional 
enhancer. Wild-type p53 is a known transcriptional activator 
(12,13). Since the H-ras element is specifically recognized 
by p53, we examined whether it could function as a p53-
dependent transcriptional enhancer. Reporter plasmids were 
constructed that contained the H-ras or the p21 or no p53 
element upstream of a minimal promoter driving expression 
of secreted alkaline phosphatase. These reporters together 
with plasmids directing expression of p53 were transiently 
transfected into Saos-2 osteosarcoma cells, which lack 
endogenous p53 (49). Wild-type p53 activated transcription 
from the reporter plasmids containing H-ras or p21 elements, 
but not from reporters lacking a p53 element or lacking a 
promoter (Table I). Consistent with their compromised DNA 
binding activities, the tumor-derived p53 mutants His273 and 
Trp248 failed to activate transcription from any of the 
reporter plasmids tested. We conclude that the H-ras 
element, although not as potent as the p21 element, can serve 
as a p53-dependent transcriptional enhancer. 
Discussion 
The p53 tumor suppressor controls cell cycle progression by 
regulating gene expression (22). The genes whose expression 
is induced by p53 invariably contain p53 binding sites within 
their regulatory regions (23-26). Interestingly, H-ras contains 
within its first intron sequences with homology to the p53 
consensus recognition site (38). We demonstrated in this 
study that wild-type p53 recognized these sequences with 
specificity and with affinity comparable to its affinity for the 
bona fide p21 element. Furthermore, the H-ras element 
functioned as a p53-dependent transcriptional enhancer in the 
context of an artificial reporter plasmid, albeit with a lower 
efficiency than the p21 element. We have therefore 
H-ras 
GGGCC TGCAG GCTGGCAC TAGCC TGCCC GGGCA CGCCS 
TGGCGCGCTCCGCCGTGGCC AGACC TGTTC 
mdm2 
GGTCA AGTTG GGACA CGTCC GGCGTCGGCTGTCGGAG GAGCT A 
AGTCC TGACA TGTCT 
p21 
GAACA TGTCC CAACA TGTTB 
gadd45 
GAACA TGTCT AAGCA TGCTG 
bax 
TCACA AGTTA G AGAÇA AGCCT 
Figure 4. Organization of the H-ras, mdm2, p21, gadd45 and bax p53 
elements. The specific pentanucleotide repeats recognized by p53 are 
underlined. The H-ras and mdm2 genes contain a fourth p53 half-site (in 
italics), whose functional significance has not been investigated yet. 
established the presence of a p53-dependent transcriptional 
'element within the H-ras gene. The most likely interpretation 
of our results is that p53 is a physiological regulator of H-ras 
expression. 
Activation of H-ras expression by p53 may seem to be a 
paradox, since p53 is a tumor suppressor (50,51) and H-ras a 
proto-oncogene (32-37). However, precedence has already 
been established for activation of proto-oncogenes by p53. 
Wild-type p53 induces expression of mdm.2, whose protein 
product functions as an oncoprotein by inhibiting the tumor 
suppressing activities of both p53 and Rb (26,29-31). 
Amplification of the mdm.2 gene or enhanced translation are 
frequently associated with human tumors (52,53). Wild-type 
p53 may therefore induce expression of two proto-oncogenes 
frequently associated with human cancer: mdm.2 and H-ras. 
The list of genes known to be regulated by p53 includes 
p21, gadd45, bax, mdm2 and H-ras (23-26). The p21 gene 
encodes an inhibitor of cyclin-dependent kinases (27,28). Its 
expression arrests cellular growth (6,23). The gadd45 gene 
participates in the cellular response to DNA damage (25), 
while bax stimulates programmed cell death (24). None of 
these three genes stimulate cell proliferation. In contrast, 
mdm2 and H-ras are proto-oncogenes. Interestingly, there are 
certain similarities in the organization of the half-sites in the 
p53 elements of the H-ras and mdm.2 genes, which are not 
shared with the p53 elements of the other genes targeted by 
p53. In H-ras there are three half-sites (Fig. 4). Two of them 
are contiguous, while the third one is 8 nucleotides upstream 
of the first two. In mdm2 there are again three half-sites (26). 
Two are contiguous, while the third one is 28 nucleotides 
downstream. In contrast to H-ras and mdm2, the half-sites in 
the p21, gadd45 and bax elements are contiguous (23-25). 
The organization of the half-sites affects the ability of p53 to 
recognize these elements. Wild-type p53 reversibly switches 
between two conformations (21,40,44,46,47). In the 
'inactive' Τ state wild-type p53 adopts dihedral symmetry, 
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en that it cannot recognize contiguous half-sites. It can 
recognize, however, non-contiguous half-sites (40). In the 
'activated' R state wild-type p53 is not locked in a dihedrally 
symmetric state and its DNA binding domains can recognize 
even contiguous half-sites (40). Thus, the presence of non­
contiguous p53 half-sites in the Η-ras and mdm2 genes may 
allow their transcription to be regulated by p53 even when it 
is in the 'inactive' Τ state. 
The p53 element in Η-ras is contained within the first 
intron. The significance of this is not understood at this time. 
Interestingly, the p53 element of mdm2 is also within the first 
intron (26). Transcription of mdm2 is initiated either at a 
promoter upstream of the first exon or at a promoter within 
the first intron. Wild-type p53 activates transcription only 
from the second promoter (54). Transcripts initiating at both 
promoters contain the entire mdm2 coding sequence, but 
differ in the efficiency with which translation is initiated at 
codon 1. Thus, the transcripts that include the first exon 
express mostly an N-terminally truncated Mdm2 protein, 
while the transcripts whose expression is induced by p53 
express full-length Mdm2 (55). The two forms of Mdm2 
differ in their functional properties. The full-length form, but 
not the truncated, can associate with the transcription 
activation domain of p53 closing a negative feedback loop, 
whereby p53 activates mdm2 transcription and Mdm2 
suppresses the transcriptional activity of p53 (26). It remains 
to be determined whether p53 induces--expression of 
transcripts initiating at the first intron of H-ras, and whether 
any functional significance can be ascribed to such 
transcripts. 
In conclusion these studies demonstrate the presence of a 
p53 transcriptional element in the Η-ras gene. The p53 tumor 
suppressor may therefore exert its cellular effects by 
coordinate activation of genes that suppress and induce cell 
proliferation. 
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